Erin M. (Ort) Bertino MD (She/Her)

Oncology•Columbus, OH

Hematologic Oncology, Thoracic Cancer

Physician

Join to View Full Profile

810 Jasonway AveSte AColumbus, OH 43214
Phone+1 614-442-3130
Fax+1 614-442-3145

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
Ohio State University HospitalResidency, Internal Medicine, 2004 - 2007
Northeast Ohio Medical UniversityClass of 2004

Certifications & Licensure

OH State Medical License 2004 - 2026
NC State Medical License 2021 - 2022
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer Start of enrollment: 2011 Feb 10
Completed
Phase 1
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
COMPLETED
PHASE1, PHASE2
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor Start of enrollment: 2012 Dec 01
Completed
Phase 1
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
ACTIVE_NOT_RECRUITING
PHASE2
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy Start of enrollment: 2020 Apr 16
ACTIVE_NOT_RECRUITING
PHASE2
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer Start of enrollment: 2020 Jun 17
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
A Phase 2 Trial of Primary Tumor Stereotactic Body Radiation Therapy Boost Before Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer.
Terence M Williams, Eric Miller, Meng Welliver, Jeremy Brownstein, Gregory Otterson
International Journal of Radiation Oncology, Biology, Physics. 2024-11-01
CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non-Small Cell Lung Cancer.
John Sharp, Daniel Jones, Julia Rotow, Panos Fidias, Erin Bertino
Journal of the National Comprehensive Cancer Network. 2024-04-05
Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
John A Sharp, Daniel Jones, Julia K Rotow, Panos M Fidias, Erin Bertino
Journal of the National Comprehensive Cancer Network. 2024-03-13

Journal Articles

Identifying Patterns of Care for Elderly Patients with Non-Surgically Treated Stage III Non-Small Cell Lung Cancer: An Analysis of the National Cancer Database
Kai He, Terence M Williams, John C Grecula, Eric D Miller, Erin M Bertino, David P Carbone, Peter G Shields, Jose G Bazan, Karl E Haglund, Gregory A Otterson, BioMed Central